In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
News|Podcasts|September 11, 2026
ACT Brief: Patient Voice in Protocol Design, AI-Informed Recruitment Workflows, and Engagement Maturity Beyond Performative
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine genuine patient partnership in trial design, how AI enables informed recruitment while preserving clinician relationships, and moving patient engagement beyond performative gestures.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part one of a new interview , Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written. When patients and caregivers say a trial was designed with them in mind, that alignment reflects input that shaped core decisions, not consultative feedback added after structure was locked. - In a
new Q&A , John Worden, chief commercial officer at Javara, discussed why AI-enabled recruitment must combine patient identification at scale with the clinician relationships that build trust. Technology should inform and enable, not displace, the physician's role in helping patients decide whether research is right for them. - In a new
feature from Pharmaceutical Executive , authors defined a maturity curve moving engagement from ad hoc, performative activities to integrated, mission-driven partnerships with measurable organizational change. Patient expectations have shifted from awareness campaigns to concrete protocol and support-service changes reflecting their input.
That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.
In today's ACT Brief, we examine how AI is surfacing endpoint options beyond traditional design thinking, why sponsor oversight of outsourced work often fails on inspection despite being robust in practice, and a new combination drug for advanced kidney cancer.
In today's ACT Brief, we examine what patient-site relationships need beyond easier technology, how to build defensible rare disease evidence from scratch, and how real-world data and AI improve enrollment screening accuracy.
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site readiness requires as therapy moves to community care, and why data harmonization is AI's primary bottleneck.
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, about why defensible trial data depends on traceability, platform ownership, and device strategy long after a study ends.
In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site burden or just shifts it, and why nine European drugmakers are sounding urgent alarms.
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
Real-World Evidence Is Moving Upstream: Is the Data Infrastructure Ready?
4
The Data Inputs That Matter Most When Pressure-Testing a Protocol's Feasibility
5